Enliven Therapeutics (NASDAQ:ELVN) Stock Price Breaks Above Fifty Day Moving Average - What's Next?

Key Points

• Enliven shares moved above their 50-day moving average of $47.25, reaching $49.66 and last trading at $49.43.
• Analysts’ average rating is “Moderate Buy”, with a consensus price target of $75.44; recent upgrades raised targets as high as $80, while two analysts rate the stock a sell.
• The company reported a quarterly loss of $0.36 per share, beating estimates of a $0.45 loss by $0.09.

Enliven Therapeutics, Inc. (NASDAQ:ELVN - Get Free Report) crossed above its fifty day moving average during trading on Friday. The stock has a fifty day moving average of $47.25 and traded as high as $49.66. Enliven Therapeutics shares last traded at $49.43, with a volume of 969,641 shares traded.

Analyst Upgrades and Downgrades

A number of equities analysts recently commented on the company. Mizuho lifted their price target on Enliven Therapeutics from $62.00 to $73.00 and gave the stock an "outperform" rating in a report on Tuesday, August 18th. The Goldman Sachs Group raised their price target on shares of Enliven Therapeutics from $67.00 to $80.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. HC Wainwright increased their price target on shares of Enliven Therapeutics from $65.00 to $73.00 and gave the stock a "buy" rating in a research note on Monday, October 19th. Zacks Research lowered shares of Enliven Therapeutics from a "hold" rating to a "strong sell" rating in a research report on Tuesday, October 13th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Enliven Therapeutics in a research note on Thursday, October 15th. Ten investment analysts have rated the stock with a Buy rating and two have given a Sell rating to the stock. According to MarketBeat, Enliven Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $75.44.

Enliven Therapeutics Price Performance

The company has a market cap of $3.62 billion, a PE ratio of -28.91 and a beta of 0.34. The company has a fifty day moving average price of $47.25 and a 200 day moving average price of $43.08.

Enliven Therapeutics (NASDAQ:ELVN - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, beating analysts' consensus estimates of ($0.45) by $0.09. As a group, sell-side analysts predict that Enliven Therapeutics, Inc. will post -1.79 EPS for the current fiscal year.

Insider Buying and Selling

In related news, Director J. Scott Garland sold 13,000 shares of Enliven Therapeutics stock in a transaction dated Thursday, October 1st. The stock was sold at an average price of $46.67, for a total value of $606,710.00. Following the completion of the transaction, the director directly owned 13,000 shares in the company, valued at approximately $606,710. This trade represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Benjamin Hohl sold 6,018 shares of the company's stock in a transaction that occurred on Monday, October 19th. The stock was sold at an average price of $38.48, for a total value of $231,572.64. Following the sale, the chief financial officer owned 38,000 shares in the company, valued at approximately $1,462,240. This represents a 13.67% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 31,054 shares of company stock valued at $1,493,823. 3.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of the stock. KBC Group NV purchased a new position in Enliven Therapeutics during the 1st quarter valued at $38,000. Three Bridge Wealth Advisors LLC bought a new position in shares of Enliven Therapeutics during the third quarter valued at $53,000. Sterling Capital Management LLC boosted its stake in Enliven Therapeutics by 1,180.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,921 shares of the company's stock valued at $88,000 after purchasing an additional 1,771 shares during the period. State of Wyoming bought a new position in Enliven Therapeutics in the 2nd quarter valued at about $96,000. Finally, ProShare Advisors LLC increased its stake in shares of Enliven Therapeutics by 29.5% during the third quarter. ProShare Advisors LLC now owns 9,852 shares of the company's stock valued at $452,000 after buying an additional 2,246 shares during the period. Institutional investors own 95.08% of the company's stock.

Enliven Therapeutics Company Profile

Enliven Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for patients with cancer. The company uses small-molecule drug discovery and development to pursue treatments designed to address validated cancer targets and improve patient outcomes.

Enliven's pipeline includes ELVN-001, an investigational BCR-ABL1 tyrosine kinase inhibitor being developed for the treatment of chronic myeloid leukemia, and ELVN-002, an investigational HER2 inhibitor intended for use in patients with HER2-positive solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.